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The guardian of the genome, p53, is often mutated in
cancer and may contribute to therapeutic resistance.
Given that p53 is intact and functional in normal
tissues, we harnessed its potential to inhibit the
growth of p53-deficient cancer cells. Specific activa-
tion of p53 in normal fibroblasts selectively induced
apoptosis in p53-deficient cancer cells. This para-
crine effect was mediated by p53-dependent secre-
tion of the tumor suppressor Par-4. Accordingly, the
activation of p53 in normal mice, but not p53/ or
Par-4/ mice, caused systemic elevation of Par-4,
which inducedapoptosisof p53-deficient tumorcells.
Mechanistically, p53 induced Par-4 secretion by sup-
pressing the expression of its binding partner, UACA,
which sequesters Par-4. Thus, normal cells can be
empowered by p53 activation to induce Par-4 secre-
tion for the inhibition of therapy-resistant tumors.INTRODUCTION
Lung cancer is the leading cause of cancer deaths in both men
and women in the United States (Siegel et al., 2012). Activation
of the Ras oncogene and loss of tumor suppressor p53 are the
two most commonly occurring alterations in lung cancer. Given
that p53 function is essential for growth arrest and cell death by
diverse chemotherapeutic agents and ionizing radiation, loss of
p53 function in the tumors may confer therapeutic resistance
ultimately leading to death of the patients (Levine, 1997; Chen
et al., 2010). P53 knockout or p53 mutant mice develop sponta-
neous aswell as inducible tumors (Donehower et al., 1992: Jacks
et al., 1994), whereas p53 transgenicmice exhibit tumor-free sur-
vival with an increased life span (Garcı´a-Cao et al., 2002).
Because up- or downregulation of transcriptional target genes
involved in cell-cycle progression or apoptosis plays an impor-
tant role in the tumor suppressor function of p53, it is not surpris-Cing that p53 is mutated within its DNA binding domain in a large
number of human cancers (Petitjean et al., 2007).
Although a major part of p53 research has focused on its cell-
autonomous functions, there is emerging evidence that tumor
latency is reduced in p53-null mice relative to wild-type mice,
indicating that p53 activity in the host may exert an inhibitory
effect on cancer progression (Kiaris et al., 2005). Moreover,
tumor progression imposes a strong selective pressure for loss
of p53 function in cancer-associated fibroblasts (Hill et al.,
2005). These observations support the view that p53 function
in both normal and cancer compartments of the tumor is impor-
tant for suppression of tumor progression. However, the precise
mechanism by which p53 loss in normal or stromal cells may
contribute to tumor progression is not well understood. Because
normal cells in the body of the patient except in the tumor micro-
environment are expected to express wild-type p53, we deter-
mined whether activation of p53 function in normal cells causes
paracrine growth inhibitory effects in cancer cells. Specifically,
we asked whether p53 activation in normal cells induces the
secretion of proapoptotic proteins systemically and whether
such proteins act to inhibit the growth of p53-deficient tumor
cells in a paracrine manner. Our findings indicate that activation
of p53 in normal cells promotes the secretion of Prostate
apoptosis response-4 (Par-4), a proapoptotic tumor suppressor
protein (Burikhanov et al., 2009). This action of p53 involves
direct inhibition of UACA (uveal autoantigen with coiled-coil
domains and ankyrin repeats), a gene first identified in patients
suffering from inflammatory eye disease (Yamada et al., 2001)
and recently reported to be upregulated by NF-kB (Burikhanov
et al., 2013 and references cited therein). Importantly, secreted
Par-4 mediates a paracrine growth-inhibitory effect by inducing
apoptosis of p53-deficient cancer cells.
RESULTS
Normal Fibroblasts Secrete Par-4 Protein in a
p53-Dependent Manner
To examine whether p53 activation in normal cells exhibits
paracrine effects in cancer cells, we used cocultures of mouseell Reports 6, 271–277, January 30, 2014 ª2014 The Authors 271
Figure 1. P53 Activation in Normal Cells
Produces Paracrine Apoptosis in p53-Defi-
cient Cancer Cells
(A) Activation of p53 in MEFs induces ap-
optosis of cocultured p53-deficient cancer cells.
Cocultures of p53+/+ or p53/ MEFs with
the indicated cancer cells were treated with
vehicle (v), Nutlin-3a (N, 10 mM), and/or PS-1145
(P, 10 mM) for 24 hr. The cells were subjected to
ICC for cytokeratins to detect epithelial cancer
cells and for active caspase-3 to determine
apoptotic cells.
(B) Apoptosis of cancer cells by CM from p53-
activated MEFs. P53+/+ or p53/ MEFs were
treated with vehicle (v), Nutlin-3a (N, 10 mM), and/
or PS-1145 (P, 10 mM) for 24 hr, and their CM was
transferred to normal (HEL) or p53-deficient
cancer (H1299) cells. Apoptotic cells were scored
after 24 hr by ICC for active caspase-3.
(C) Coparallel activation of p53 and inhibition of
NF-kB activity additively increases Par-4 secretion
in fibroblasts. MEFs were treated with vehicle (v),
Nutlin-3a (N), and/or PS-1145 (P) for 24 hr, and
their CM, as well as whole-cell lysates, was sub-
jected to western blot analysis for Par-4. b-actin
was used to normalize loading of lysate. Coo-
massie blue-stained albumin in the serum was
used to normalize loading of CM. Par-4 secretion,
but not Col1A1 secretion, was dependent on the
p53 status of the cells. Fold change in secreted
Par-4 is shown.
(D) Par-4 secretion is critical for the paracrine
effect resulting from simultaneous p53-activation
and NF-kB-inhibition. The CM from p53+/+ cells
treated with Nutlin-3a + PS-1145 was incubated
with polyclonal antibody for Par-4 or PTEN control
and then added to H1299 cells. Apoptosis of
H1299 cells was scored after 24 hr by ICC for
active caspase 3 (left panel). Par-4+/+ and Par-4/
MEFswere treatedwith Nutlin-3a + PS-1145 (N+P)
or vehicle, and then the CM was applied to the
indicated cell lines, and apoptotic cells were scored by ICC for active caspase-3 (middle panel). Expression of Par-4 in CM was verified on western blots (right
panel).
Asterisks in (A), (B), and (D) indicate statistical significance (p < 0.001) by the Student’s t test; **N+P is significantly (p < 0.001) more effective than individual
treatments based on two-way ANOVA. Error bars indicate SD.embryonic fibroblasts (MEFs) from p53+/+ or p53/ mice with
p53-null H1299 and PC-3 cells and p53 mutant HOP92 cells.
The cell cultures were treated with Nutlin-3a, a specific activator
of p53 (Vassilev et al., 2004). Nutlin-3a induced apoptosis in
p53-deficient cancer cells that were cocultured with p53+/+
MEFs but not with p53/ MEFs (Figure 1A, left). As expected,
the p53-deficient cancer cells and the MEFs were resistant to
apoptosis by Nutlin-3a when cultured individually (Figure 1A,
right). Because p53 may function by partial inhibition of NF-kB
activity (Dey et al., 2007), we combined Nutlin-3a with PS-
1145, a small molecule that specifically inhibits IKKb (see
Burikhanov et al., 2013). By itself, PS-1145 does not induce
apoptosis of normal or lung cancer cells (Figure 1A, right;
Burikhanov et al., 2013). However, treatment of the cocultures
with PS-1145 induced apoptosis in cancer cells, and the combi-
nation of Nutlin-3a plus PS-1145 highly augmented that effect
(Figure 1A).272 Cell Reports 6, 271–277, January 30, 2014 ª2014 The AuthorsTo determine whether extracellular factors secreted by the
MEFs in response toNutlin-3a and/or PS-1145 treatment contrib-
uted to apoptosis of the cancer cells, the MEFs were treated with
these small molecules, and conditioned medium (CM) was trans-
ferred to p53-deficient lung cancer cells or normal lung cells. The
CM from p53+/+ MEFs but not the CM from p53/MEFs treated
with Nutlin-3a or PS-1145 produced apoptosis of H1299 cells
(Figure 1B). Moreover, the CM from p53+/+ MEFs treated with a
combination of Nutlin-3a and PS1145 exhibited an additive
apoptotic effect in H1299 cells (Figure 1B). By contrast, the CM
fromMEFs treated with Nutlin-3a and/or PS-1145 did not induce
apoptosis in wild-type TP53 primary human lung fibroblasts HEL
cells (Figure 1B). Similarly, CM fromHEL cells treated with Nutlin-
3a plus PS-1145 induced apoptosis of H1299 and HOP92 cells,
but not in HEL cells (Figure S1A). These findings indicated that
Nutlin-3a and PS-1145 may regulate the secretion of cancer-
selective proapoptotic factor(s) in a p53-dependent manner.
Figure 2. Activation of p53 in Mice Induces
Systemic Expression of Par-4 Proapoptotic
Activity
(A) P53 function is essential for induction of sys-
temic Par-4 in mice. Serum samples from p53+/+
mice (4 ml per lane) and p53/mice (8 ml per lane)
(left panel) and also from p53+/+, p53/, and
Par-4/ mice (right panel) injected via i.p. route
with either vehicle (v) or with Nutlin-3a + PS-1145
(N+P) were examined for Par-4 expression by
western blot analysis using serum albumin to
normalize loading. Data are representative of four
mice per treatment.
(B) Serum from Nutlin-3a plus PS-1145-treated
p53+/+ mice induces ex vivo apoptosis of cancer
cells. Serum samples collected from p53+/+,
p53/, and Par-4/ mice injected i.p. with either
vehicle (lower panel) or with Nutlin-3a + PS-1145
(N+P) (upper panel) was applied at a final con-
centration of 10% to the indicated normal or
cancer cell lines. The cells were scored for
apoptosis after 24 hr. Fetal bovine serum (FBS,
10%) was used as an additional control.
(C) Secreted Par-4 is essential for the paracrine
effect of p53 activation. Serum samples collected
from p53+/+ mice treated with vehicle or Nutlin-
3a + PS-1145 (N+P) were preincubated with Par-4
antibody, control PTEN antibody or no antibody
(no antibody [Ab]), and then applied on lung cancer
cells. After 24 hr of treatment, the cells were
scored for apoptosis.
Asterisks in (A) and (B) indicate statistical signifi-
cance (p < 0.001) by the Student’s t test. Error bars
indicate SD.We then examined the CM for secreted proteins, especially
TRAIL, maspin, IGFBP3, and Par-4, which are known to act
extracellularly and induce cancer-specific apoptosis. The CM
from p53+/+ MEFs treated with Nutlin-3a or PS-1145 showed
elevated levels of Par-4 protein, and combination of Nutlin-3a
plus PS-1145 additively increased the secretion of Par-4 (Fig-
ure 1C). None of the other proteins showed elevated secretion
with Nutlin-3a plus PS-1145 (R.B. and T.S.-B., unpublished
data). By contrast, p53/ MEFs accumulated Par-4 protein in
the lysate but failed to secrete it in response to these treatments
(Figure 1C). However, secretion of Collagen (Col1A1) was unaf-
fected by the treatments in p53+/+ or p53/ MEFs, implying
that p53/ MEFs were not generally deficient in protein secre-
tion (Figure 1C, bottom). Moreover, pretreatment of p53+/+ cells
with pan-caspase inhibitor z-VAD-fmk did not diminish Nutlin-3a
plus PS-1145-inducible secretion of Par-4 protein, indicating
that Par-4 secretion was not a postapoptosis event (Figure S1B).
Importantly, the Par-4 antibody but not the PTEN control anti-
body inhibited apoptotic activity in the CM (Figure 1D, left),
implying that secreted Par-4 mediates the paracrine apoptotic
action of p53. Consistent with these observations, the CMCell Reports 6, 271–277from Par-4+/+ MEFs but not Par-4/
MEFs treated with Nutlin-3a plus PS-
1145 induced apoptosis of p53-deficient
cancer cells (Figure 1D, middle and right).Moreover, doxorubicin, which is known to activate p53, induced
Par-4 secretion from Par-4+/+ but not Par-4/ MEFs, and
the CM collected from Par-4+/+ but not Par-4/ MEFs
induced apoptosis of p53-deficient cancer cells (Figure S1D).
Together, these findings suggest that p53 regulates the
secretion of Par-4 protein, which selectively induces apoptosis
in cancer cells.
P53 Induces Systemic Expression of Par-4 in Normal
Mice
We interrogated whether p53 regulates the secretion of Par-4
in vivo. The serum of untreated C57BL/6 p53+/+ mice contained
higher levels of Par-4 relative to p53/ mice (Figure 2A, left).
When p53+/+, p53/, and Par-4/ mice were injected with
Nutlin-3a plus PS-1145 or vehicle control, and serum samples
were collected for analysis of Par-4, we noted that, relative to
vehicle control, Nutlin-3a plus PS-1145 caused a 5-fold
increase in serum levels of Par-4 protein in p53+/+ mice (Fig-
ure 2A, right). By contrast, Nutlin-3a plus PS-1145 failed to
elevate systemic levels of Par-4 in p53/ mice or Par-4/
mice (Figure 2A, right), implying that p53 function was essential, January 30, 2014 ª2014 The Authors 273
Figure 3. P53 Stimulates Par-4 Secretion by
Suppressing the Expression of UACA
(A) P53 downregulates UACA. Whole-cell lysates
from p53+/+ and p53/ MEFs that were either
untreated or treated with vehicle (v), Nutlin-3a (N,
10mM), or PS-1145 (P, 10 mM) for 24 hr (left three
panels), or whole-tissue lysates of highly vascular
organs obtained from p53+/+ and p53/ mice
(right three panels) were examined for UACA by
western blot analysis.
(B) Restoration of p53 activity inhibits UACA
expression and promotes Par-4 secretion. P53/
MEFs were infected with GFP-tagged p53- or
GFP-producing adenoviral constructs (left panel).
Also, the mouse fibroblasts (10)1, which do not
express any p53, and (10)1-derived Val5 cells,
which are engineered to stably overexpress wild-
type p53 at 32C or mutant p53 at 37C, were
grown at 37C or shifted to 32C to activate p53
(right panel). Expression of the indicated proteins
in the CM or whole-cell lysate was examined by
western blot analysis.
(C) UACA inhibits Par-4 secretion. UACA expres-
sion was knocked down in mouse (p53+/+ or
p53/ MEF) and human (HEL) cells with distinct
siRNA pools from two different sources, Dhar-
macon (D) and Santa Cruz Biotechnology (SC),
and the CM, as well as the whole-cell lysates, was
subjected to western blot analysis. C, control
(scrambled) siRNA.
(D) P53 activation and UACA inhibition promotes
secretion by a BFA-sensitive pathway. (10)1/Val5
fibroblasts grown at 32C were treated with BFA
(1 mg/ml) or vehicle (v) for 3 hr (left panel). UACA
expression was inhibited in MEFs (p53+/+) with
Nutlin-3a plus PS-1145 (N+P; 10 mM each) (middle
panel), or with an siRNA pool (from Dharmacon)
(right panel), and then the cells were further placed
in the presence of BFA or vehicle (v) for 3 hr. The
CM, as well as the whole-cell lysates, was sub-
jected to western blot analysis.for upregulation of Par-4 secretion in mice. Importantly, the
serum from Nutlin-3a plus PS-1145-treated p53+/+ mice, but
not p53/ mice or Par-4/ mice, induced ex vivo apoptosis
of cancer cell cultures but not normal cell cultures (Figure 2B,
top). By contrast, the serum from vehicle-treated mice failed to
induce apoptosis over background levels in normal or cancer
cells (Figure 2B, bottom). Moreover, preincubation of the serum
samples collected from Nutlin-3a plus PS-1145-treated p53+/+
mice with the Par-4 antibody but not the PTEN control antibody
significantly inhibited the ability of the serum to induce apoptosis
of cancer cell cultures (Figure 2C). Altogether, these findings
suggest that p53 activation in normal mice induces adequate
levels of systemic Par-4 protein that is functionally effective in
inducing apoptosis of cancer cells.274 Cell Reports 6, 271–277, January 30, 2014 ª2014 The AuthorsP53 Downregulates the Expression
of UACA to Induce Par-4 Secretion
Because Par-4 does not contain a p53
consensus binding site in its DNA, Par-4
secretion is likely regulated by anotherdownstream target of p53. To identify the primary gene target
of p53, we used three criteria: (1) it should encode a protein
that binds to Par-4, (2) it should be regulated by p53, and (3) it
should be induced by NF-kB activity. We recently identified
UACA as a strong binding partner of Par-4 (Burikhanov et al.,
2013). UACA was coimmunoprecipitated from normal MEF and
HEL fibroblast with Par-4 antibody, and Par-4 was reciprocally
coimmunoprecipitatedwith UACA antibody (Figure S2A). A com-
parison of p53+/+ and p53/ MEFs indicated that UACA was
lower in p53+/+ normal cells and mouse tissues relative to
p53/ cells and mouse tissues (Figure 3A). UACA levels in
p53+/+ and p53/ MEFs correlated inversely with the levels of
Par-4 secreted in the CM (Figure S2B). Nutlin-3a suppressed
the expression of UACA in p53+/+ but not p53/ MEFs
Figure 4. P53 Directly Binds to UACA and Inhibits Its Expression
(A) P53 binds to its consensus binding motif in UACA. HEL cells were treated
with Nutlin-3a (N) or vehicle (v) for 24 hr and subjected to chromatin immu-
noprecipitation analysis with p53 antibody (Ab) or control rabbit immuno-
globulin (Ig) G Ab, and immunoprecipitated DNA fragments were analyzed by
PCR with primers flanking the p53-binding site in UACA. Primers flanking the
p53-binding motif #1 in p21 (see Figure S3A) or for GAPDH (which does not
contain a p53-binding site) were used as positive or negative control,
respectively. Input samples for each set of primers are shown.
(B) Nutlin-3a causes inhibition of endogenous UACA expression in an NF-kB-
independent manner. IKKb/ MEFs or HEL cells were treated with Nutlin-3a
or vehicle for 24 hr, and whole-cell lysates were subjected to western blot
analysis for UACA, p53, or actin.(Figure 3A). Our previous studies (Burikhanov et al., 2013) have
shown that UACA is regulated by NF-kB, and, as expected,
UACA expression was inhibited by PS-1145 (Figure 3A). Resto-
ration of p53 activity in p53/MEFs by p53-adenoviral infection
or at 32C in (10)1/Val5 fibroblasts, which contain a temperature-
sensitive mutant of p53 (Wu and Levine, 1994), suppressed the
expression of UACA and induced secretion of Par-4 (Figure 3B).
Moreover, knockdown of UACA using several different mouse
and human small interfering RNA (siRNA) duplex pools resulted
in elevated Par-4 levels in the CM of p53+/+ MEFs and HEL cells
(Figure 3C). By contrast, knockdown of UACA in p53/ MEFs
did not elevate the secretion of Par-4 (Figure 3C), indicating
that p53 function was necessary to regulate the secretion of
Par-4. Consistently, ectopic expression of UACA inhibited the
secretion of Par-4 (Figure S2C). UACA binding to Par-4 was
essential to prevent Par-4 secretion, and, accordingly, mutant
UACA (631–1,413 aa), which does not bind to Par-4 (Burikhanov
et al., 2013), was unable to prevent Par-4 secretion (Figures S2D
and S2E).
UACAand p53Reciprocally Regulate Par-4 Secretion via
the Classical Pathway
Previous studies have indicated that Par-4 is secreted via the
classical endoplasmic reticulum (ER)-Golgi pathway (BurikhanovCet al., 2009), as well as via the exosomal pathway (Wang et al.,
2012). On the other hand, p53 has been shown to promote
secretion of proteins via the exosomal pathway (Yu et al.,
2009). To determinewhether p53 activation leads to Par-4 secre-
tion via the classical pathway, we used Brefeldin A (BFA), which
blocks the ER-Golgi pathway. BFA inhibited the secretion of
Par-4 by p53 restoration at 32C in (10)1/Val5 fibroblasts (Fig-
ure 3D, left panel). As both Nutlin-3a and PS-1145 induced the
secretion of Par-4 in a p53-dependent manner, we investigated
whether Par-4 secretion following Nutlin-3a plus PS-1145-
treatment occurred via the classical pathway. Nutlin-3a plus
PS-1145-inducible secretion of Par-4 from p53+/+ MEFs was
about 60% inhibited by BFA (Figure 3D, middle panel). These
findings imply that p53 regulates the secretion of Par-4 largely
by the classical pathway. Moreover, Par-4 secretion following
UACA knockdown in p53+/+ MEFs was inhibited by BFA (Fig-
ure 3D, right). Collectively, these findings indicate that UACA
inhibition by siRNA, Nutlin-3a plus PS-1145, or p53 activation
induces Par-4 secretion via the classical pathway.
UACA Is a Direct Target of p53
A potential p53-binding site (el-Deiry et al., 1992) is present in the
DNA corresponding to exon 1 within the coding region of UACA
(Figure S3A). P53 suppresses the expression of UACA RNA, as
judged by quantitative RT-PCR (qRT-PCR) (Figure S3B). To
determine direct binding of p53 to its consensus binding site in
UACA, we performed chromatin immunoprecipitation studies.
HEL cells treated with Nutlin-3a, but not with vehicle, showed
chromatin immunoprecipitation of endogenous p53 bound to
the p53-consensus motif in UACA (Figure 4A). These findings
were corroborated by chromatin immunoprecipitation studies
in p53-deficient cells that were transfected with p53 expression
construct (Figure S3C). Consistently, Nutlin-3a treatment, which
activates endogenous p53, suppressed the expression of UACA
in HEL cells (Figure 4B).
To determine whether p53 regulated UACA expression via its
binding motif in an NF-kB activity-independent manner, we per-
formed experiments in IKKb/MEFs, which lack NF-kB activity
(Burikhanov et al., 2013; Li et al., 1999). Nutlin-3a treatment of
IKKb/MEFs resulted in suppression of UACA expression (Fig-
ure 4B). Moreover, ectopic p53 suppressed the expression of
UACA containing the p53-binding motif but did not suppress
the expression of mutant-UACA, which contained mutations in
the p53-binding sequence, in IKKb/ MEFs (Figure S4).
Together, these findings suggest that p53 suppressed the
expression of UACA via its binding motif in an NF-kB-indepen-
dent manner. Thus, UACA is a relevant target of p53, and p53
may regulate Par-4 secretion by downregulation of UACA.
DISCUSSION
The tumor suppressor p53 is known to suppress tumor growth
by intracellular activation of growth arrest and apoptotic cell
death pathways. However, p53 is mutated in over 50% of
cancers, and mutant forms of p53 may render cancer cells resis-
tant to both chemotherapy and radiation therapy. Lung cancer,
the leading cause of cancer-related deaths in the US, is often
associated with inactivating mutations in p53. We determinedell Reports 6, 271–277, January 30, 2014 ª2014 The Authors 275
whether wild-type p53 function in normal cells could be effec-
tively propelled to target lung cancer cells. The present study re-
vealed that p53 activation in normal cells induces paracrine
apoptosis of p53-deficient lung cancer and prostate cancer
cells. This action of p53 is mediated by the tumor suppressor
protein Par-4. The paracrine effect of p53 activation on Par-4
secretion was bolstered by coparallel inhibition of NF-kB activity
in normal cells. We noted that UACA binds to Par-4 and prevents
it from being secreted, and inhibition of UACA by p53 activation
and/or inhibition of NF-kBactivity, or by several different siRNAs,
results in elevated secretion of Par-4. Importantly, Par-4
secreted by cells following coparallel activation of p53 and inhi-
bition of NF-kB activity caused apoptosis in p53-deficient lung
cancer cells but not normal cells. The physiological relevance
of the findings was confirmed by studies indicating that normal
cells in mice can be triggered to secrete proapoptotic Par-4
activity in circulation in a p53-dependent manner. The elevated
levels of Par-4 in serum induced ex vivo apoptosis in tumor cells
but not normal cells. Because our previous studies indicated a
good correlation between inhibition of lung tumors in immuno-
competent mice and induction of ex vivo apoptosis by Par-4 in
the serum of these mice (Zhao et al., 2011), the activation of
p53 to trigger proapoptotic Par-4 protein secretion and elevate
its systemic levels may be an effective strategy to induce
apoptosis of cancer cells that metastasize through the circula-
tory route. Collectively, our findings suggest that secreted
Par-4 mediates the paracrine apoptotic effects of p53, and that
secretagogues of Par-4 may therefore empower normal cells
to execute paracrine tumor growth inhibition.
Our findings indicate that Par-4 secretion following p53 activa-
tion occurs via the classical BFA-sensitive pathway. Secretion of
Par-4 via this pathway is dependent on downmodulation of
UACA, a functional target of p53. Chromatin immunoprecipita-
tion experiments confirmed that p53 directly binds to its
consensus motif in UACA. Importantly, p53 suppressed the
expression of UACA in an NF-kB-independent manner. Given
that UACA is a principal binding partner that sequesters Par-4
in normal cells, UACA inhibition by p53 is necessary to release
Par-4 for secretion via the classical pathway. However, normal
cells lacking p53 are deficient in Par-4 secretion despite UACA
downregulation, implying that p53 function is critical for Par-4
secretion and is suggestive of an additional role for p53 in
triggering Par-4 secretion. Several integral components of the
classical ER-Golgi-transport vesicle/membrane fusion pathway
are currently being investigated as targets for p53-dependent
Par-4 secretion. Given that previous studies have indicated
that p53 regulates protein secretion via the exosomal pathway,
we tested whether Par-4 secretion is also regulated via the
exosomes. Our findings indicate that, of the total Par-4 secreted
by cells, <5% is secreted via the exosomal pathway, and the
large majority is secreted by the classical pathway (T.S.-B.,
unpublished data).
In summary, our findings suggest that the tumor suppressor
p53 regulates the secretion of the proapoptotic, tumor sup-
pressor Par-4 via the classical pathway by suppressing UACA,
and that Par-4 executes the paracrine apoptotic effects of p53.
As systemic Par-4 inhibits the growth of lung tumors (Zhao
et al., 2011), Par-4 secretagogues can be exploited to activate276 Cell Reports 6, 271–277, January 30, 2014 ª2014 The Authorsp53 and unleash the power of normal cells in the tumor micro-
and macroenvironment to elevate systemic Par-4 and suppress
tumor cell survival.
EXPERIMENTAL PROCEDURES
Cells and Chemical Reagents
Lung cancer cells H1299, HOP92, LLC1, prostate cancer cells PC-3, and
primary lung fibroblast cells HEL were from ATCC. IKKb+/+ and IKKb/
MEFs were previously described (Burikhanov et al., 2013). Par-4+/+ and
Par-4/ MEFs were derived from wild-type and Par-4-null C57BL/6 mice,
respectively (Figure S1C). KP lung tumor cells, and P53+/+ and p53/ MEFs
in the third passage were from Tyler Jacks (Massachusetts Institute of
Technology). Nutlin-3a was from Cayman Chemicals.
Immortalized Balb/c fibroblasts (10)1, with no endogenous p53, and (10.1)
Val5 cell line derived from (10)1 cells by stable transfection with the tempera-
ture-sensitive p53 allele encoding valine at 135 aa, were from Arnold Levine
(Institute for Advanced Study, NJ). The p53 mutant in (10.1)Val5 cells exhibits
wild-type conformation at 32C, judged by p21/WAF1 induction, and mutant
conformation at 37C–39C (Wu and Levine, 1994).
Animal Experiments
Whole-blood samples and various tissues were collected frommice 24 hr after
injection via the intraperitoneal (i.p.) route with Nutlin-3a plus PS-1145 (10 and
5mg/kg bodyweight, respectively) or corn oil (100 ml) as vehicle control. Serum
was separated from the blood samples and used for testing. All animal
procedures were performed with IACUC approval.
Statistical Analysis
All experiments were performed in triplicate to verify the reproducibility of the
findings. Statistical analyses were carried out with Statistical Analysis System
software (SAS Institute). Mean ± SD bars are shown. p values were calculated
using the Student’s t test.
All other reagents and experimental procedures are presented in the
Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2013.12.020.
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